Clostridium tetani Infections is an indication for drug development with over 50 pipeline drugs currently active. According to GlobalData, preregistered drugs for Clostridium tetani Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Clostridium tetani Infections compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Clostridium tetani Infections overview
Clostridium tetani infections are a serious disease of the nervous system that cause painful muscle contractions, especially in the jaw and neck. The disease is also known as lockjaw. The bacteria enter the body through deep cuts or wounds that are contaminated with soil, dust, manure, or saliva. The bacteria produce a toxin that affects the nervous system and can lead to complications such as broken bones, respiratory failure, and death. Tetanus can be prevented by immunization with tetanus-toxoid-containing vaccines (TTCV) and proper wound care. Tetanus is not transmitted from person to person.
For a complete picture of PTSR and LoA scores for drugs in Clostridium tetani Infections, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
